Redhawk Wealth Advisors Inc. Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Redhawk Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 319.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,209 shares of the biopharmaceutical company’s stock after buying an additional 13,108 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Bristol Myers Squibb were worth $992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Norges Bank purchased a new position in Bristol Myers Squibb in the 4th quarter valued at approximately $1,947,272,000. AQR Capital Management LLC increased its position in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Finally, Man Group plc boosted its position in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst earnings estimates increased: Erste Group Bank raised its FY2026 EPS forecast for BMY to $6.96 from $6.34, matching the broader consensus, and lifted its FY2027 estimate to $6.51 from $6.10. The revisions suggest improving confidence in the company’s earnings outlook. Bristol Myers Squibb earnings estimate revisions
• Positive Sentiment: $2.3 billion Houston manufacturing campus: BMY plans to build an approximately 600,000-square-foot advanced manufacturing and life sciences facility at Generation Park in Houston. The project is expected to create about 500 permanent jobs and roughly 2,000 construction jobs, expanding the company’s U.S. production capacity and supporting its previously announced $40 billion domestic investment commitment. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Neutral Sentiment: Broker sentiment remains favorable but not strongly bullish: BMY continues to carry an average “Moderate Buy” recommendation. Recent commentary highlights the company’s growth portfolio and pipeline, but also cautions that generic competition and the stock’s prior gains could limit near-term upside. Bristol Myers Squibb receives Moderate Buy recommendation
• Negative Sentiment: Merger speculation is unconfirmed: Reports that BMY held merger discussions with AstraZeneca helped send AZN sharply lower, but neither company confirmed the talks. The lack of confirmation and skepticism from Wall Street may weigh on BMY by raising questions about deal costs, integration risks and strategic priorities, even though a combination would create one of the world’s largest drugmakers. AstraZeneca versus Bristol Myers Squibb merger speculation

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BMY. Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Citigroup reaffirmed a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Truist Financial reiterated a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Guggenheim reissued a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Trading Down 1.8%

Shares of Bristol Myers Squibb stock opened at $63.66 on Wednesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The business’s fifty day moving average is $59.09 and its two-hundred day moving average is $58.80. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm has a market cap of $130.05 billion, a PE ratio of 14.02, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm posted $1.46 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.